Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines

After worldwide implementation of 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10/PCV13), a 20-valent PCV (PCV20) was developed. We assessed dynamics of non-PCV13 additional PCV20 serotypes (VT20–13), compared with all other non-VT20 serotypes, in children <2 years of age in late...

Full description

Bibliographic Details
Main Authors: Shalom Ben-Shimol, Noga Givon-Lavi, Leore Kotler, Bart Adriaan van der Beek, David Greenberg, Ron Dagan
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2021-01-01
Series:Emerging Infectious Diseases
Subjects:
pneumococcal vaccine
vaccines
Streptocococcus pneumoniae
bacteria
respiratory infections
Israel
Online Access:https://wwwnc.cdc.gov/eid/article/27/1/20-1178_article

Internet

https://wwwnc.cdc.gov/eid/article/27/1/20-1178_article

Similar Items